Showing 1 to 1 of 1 results
cincodias.elpais.com
🌐 65% Global Worthiness
Oryzon Genomics Raises €30 Million, Bolsters Nasdaq Bid
Oryzon Genomics, a Spanish pharmaceutical company, raised €30 million in an accelerated capital increase led by a US institutional investor, exceeding its initial target, to support its potential Nasdaq dual listing and advance its clinical programs.
Oryzon Genomics Raises €30 Million, Bolsters Nasdaq Bid
Oryzon Genomics, a Spanish pharmaceutical company, raised €30 million in an accelerated capital increase led by a US institutional investor, exceeding its initial target, to support its potential Nasdaq dual listing and advance its clinical programs.
Progress
44% Bias Score
Decent Work and Economic Growth
Showing 1 to 1 of 1 results